Infectious Disease
Viral Pneumonia
11
Pipeline Programs↗
0
Active Trials↗
8
Companies Involved↗
Viral Pneumonia is an emerging landscape with 11 programs across 8 companies. The most active players are Asia Cell Therapeutics (Shanghai) Co., Ltd., EMD Serono, Merck & Co.. 2 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 12
Phase 24
Phase 31
Analysis
Modality Breakdown
11programs
Small molecule655%
Monoclonal antibody327%
Cell therapy218%
Modality classified for 100% of 12 pipeline programs.
Analysis
Trial Status
4
clinical trials
Unknown status2 · 50%
Withdrawn1 · 25%
Terminated1 · 25%
Clinical Trials
Trial Activity
Yinhu Qingwen Granule in the Treatment of Viral Pneumonia
Unknown status·—·Phase 1·NCT04955223·60 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)